The STAT3dODN sequesters STAT3 transcription factors in the cytoplasm, thereby reducing expression of oncogenic STAT3 target genes. Additionally, treatment with the dODN results in increased expression of costimulatory molecules that recruit T cells and activate an effective anti-AML immune response.